Latest news with #Apisolex™
Business Wire
5 days ago
- Business
- Business Wire
Lubrizol's Apinovex™ Polymer Wins CPhI China's 2025 Pharma Excipient Award
CLEVELAND--(BUSINESS WIRE)--Lubrizol's Apinovex™ polymer was the proud recipient of a Celebration Award in the Pharma Excipients Award category at CPhI China, held in Shanghai, June 24-26. CPhI supports the global Pharma supply chain with multi-channel events and digital platforms in every region, where industry professionals can meet, learn and collaborate on APIs, CDMOs, excipients and more. Apinovex™ polymer's win places it alongside another Lubrizol novel excipient, Apisolex™ polymer, with multiple awards, including CPhI's 2023 Global Innovation Award and recognition as the Grand Winner of the 2023 Annual Medicine Maker Innovation Award. Share Apinovex polymer's win places it alongside another of Lubrizol's novel excipients, Apisolex™ polymer, with multiple awards, including CPhI's 2023 Global Innovation Award and recognition as the Grand Winner of the 2023 Annual Medicine Maker Innovation Award. These awards underscore Lubrizol's commitment to bringing the next generation of excipient technology to market, improving solubility and bioavailability of APIs to enhance drug delivery. 'We are excited to have received this additional recognition from CPhI following the earlier receipt of innovation awards for our novel injectable excipient, Apisolex™ polymer,' says Matt Finkelhor, Global Commercial Manager, Novel Polymers, Lubrizol. 'The awards confirm that Lubrizol's innovation is making a difference in drug delivery solutions that improve bioavailability to help bring more life-changing medications to market.' The CPhI awards include nine award categories across the entire pharmaceutical industry, fully showcasing outstanding achievements in innovation, design, ingredients and excipients. The Pharma Excipients Award recognizes innovative products with high market potential, focusing on improving the technical standards of the pharmaceutical excipients industry, shaping outstanding examples in the global pharmaceutical excipients field, and leading to new trends in industry development. About Lubrizol Lubrizol, a Berkshire Hathaway company, is a science-based company whose specialty chemistry delivers sustainable solutions to advance mobility, improve well-being and enhance modern life. Every day, the innovators of Lubrizol strive to create extraordinary value for customers at the intersection of science, market needs and business success, driving discovery and creating breakthrough solutions that enhance life and make the world work better. Founded in 1928, Lubrizol has global reach and local presence, with over 100 manufacturing facilities, sales and technical offices and over 7,000 employees worldwide. For more information, visit
Yahoo
09-06-2025
- Business
- Yahoo
Lubrizol Announces an Important Milestone for Its Novel Patented Excipient, Apisolex™ Polymer
CLEVELAND, June 09, 2025--(BUSINESS WIRE)--Lubrizol announces that an Apisolex™ polymer excipient-enabled drug formulation is in Phase 1 clinical trials. Introduced to the market in 2022, Apisolex polymer excipient is a polyamino acid-based polymer that enhances the solubility of BCS Class II and IV active pharmaceutical ingredients (API). Apisolex polymer excipient is manufactured following Good Manufacturing Practices (GMP) guidelines and can be used in dosage forms for various routes of administration, including parenteral. The use of Apisolex polymer excipient has been proven to increase the solubility of certain APIs by as much as 50,000-fold. Apisolex polymer excipient is currently being evaluated in multiple programs across the globe, enabling delivery of hard-to-formulate APIs from various therapeutic classes and by multiple routes. Kevin Song, Senior Director, Global Pharmaceutical and Nutraceutical Business, notes "the progression to clinical trials of a medicinal product formulated with Apisolex polymer excipient demonstrates its ability to provide differentiated solutions to solubility and bioavailability challenges in parenteral formulations." Song adds, "Lubrizol continues to invest in expanding the reach of the Apisolex polymer excipient across global markets and nurturing relationships with drug product manufacturers that are facing insoluble API challenges." About Lubrizol Lubrizol, a Berkshire Hathaway company, is a science-based company whose specialty chemistry delivers sustainable solutions to advance mobility, improve well-being and enhance modern life. Every day, the innovators of Lubrizol strive to create extraordinary value for customers at the intersection of science, market needs and business success, driving discovery and creating breakthrough solutions that enhance life and make the world work better. Founded in 1928, Lubrizol has global reach and local presence, with over 100 manufacturing facilities, sales and technical offices and over 7,000 employees worldwide. For more information, visit View source version on Contacts MEDIA CONTACT Lori Ditty, Global Marketing
Yahoo
09-06-2025
- Business
- Yahoo
Lubrizol Announces an Important Milestone for Its Novel Patented Excipient, Apisolex™ Polymer
CLEVELAND, June 09, 2025--(BUSINESS WIRE)--Lubrizol announces that an Apisolex™ polymer excipient-enabled drug formulation is in Phase 1 clinical trials. Introduced to the market in 2022, Apisolex polymer excipient is a polyamino acid-based polymer that enhances the solubility of BCS Class II and IV active pharmaceutical ingredients (API). Apisolex polymer excipient is manufactured following Good Manufacturing Practices (GMP) guidelines and can be used in dosage forms for various routes of administration, including parenteral. The use of Apisolex polymer excipient has been proven to increase the solubility of certain APIs by as much as 50,000-fold. Apisolex polymer excipient is currently being evaluated in multiple programs across the globe, enabling delivery of hard-to-formulate APIs from various therapeutic classes and by multiple routes. Kevin Song, Senior Director, Global Pharmaceutical and Nutraceutical Business, notes "the progression to clinical trials of a medicinal product formulated with Apisolex polymer excipient demonstrates its ability to provide differentiated solutions to solubility and bioavailability challenges in parenteral formulations." Song adds, "Lubrizol continues to invest in expanding the reach of the Apisolex polymer excipient across global markets and nurturing relationships with drug product manufacturers that are facing insoluble API challenges." About Lubrizol Lubrizol, a Berkshire Hathaway company, is a science-based company whose specialty chemistry delivers sustainable solutions to advance mobility, improve well-being and enhance modern life. Every day, the innovators of Lubrizol strive to create extraordinary value for customers at the intersection of science, market needs and business success, driving discovery and creating breakthrough solutions that enhance life and make the world work better. Founded in 1928, Lubrizol has global reach and local presence, with over 100 manufacturing facilities, sales and technical offices and over 7,000 employees worldwide. For more information, visit View source version on Contacts MEDIA CONTACT Lori Ditty, Global Marketing Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
09-06-2025
- Business
- Business Wire
Lubrizol Announces an Important Milestone for Its Novel Patented Excipient, Apisolex™ Polymer
CLEVELAND--(BUSINESS WIRE)--Lubrizol announces that an Apisolex™ polymer excipient-enabled drug formulation is in Phase 1 clinical trials. Introduced to the market in 2022, Apisolex polymer excipient is a polyamino acid-based polymer that enhances the solubility of BCS Class II and IV active pharmaceutical ingredients (API). Apisolex polymer excipient is manufactured following Good Manufacturing Practices (GMP) guidelines and can be used in dosage forms for various routes of administration, including parenteral. The use of Apisolex polymer excipient has been proven to increase the solubility of certain APIs by as much as 50,000-fold. Apisolex polymer excipient is currently being evaluated in multiple programs across the globe, enabling delivery of hard-to-formulate APIs from various therapeutic classes and by multiple routes. Kevin Song, Senior Director, Global Pharmaceutical and Nutraceutical Business, notes 'the progression to clinical trials of a medicinal product formulated with Apisolex polymer excipient demonstrates its ability to provide differentiated solutions to solubility and bioavailability challenges in parenteral formulations.' Song adds, 'Lubrizol continues to invest in expanding the reach of the Apisolex polymer excipient across global markets and nurturing relationships with drug product manufacturers that are facing insoluble API challenges.' About Lubrizol Lubrizol, a Berkshire Hathaway company, is a science-based company whose specialty chemistry delivers sustainable solutions to advance mobility, improve well-being and enhance modern life. Every day, the innovators of Lubrizol strive to create extraordinary value for customers at the intersection of science, market needs and business success, driving discovery and creating breakthrough solutions that enhance life and make the world work better. Founded in 1928, Lubrizol has global reach and local presence, with over 100 manufacturing facilities, sales and technical offices and over 7,000 employees worldwide. For more information, visit
